Clinical Trials Directory

Trials / Completed

CompletedNCT01360749

Efficacy and Safety of Lambdalina (Lidocaine Cream) Versus Placebo as an Anesthetic for Laser Hair Removal

Multicentre, Double-Blind Trial to Evaluate the Efficacy and Safety of Lambdalina vs Placebo as an Anesthetic for Laser Hair Removal

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
42 (actual)
Sponsor
ISDIN · Industry
Sex
Female
Age
18 Years – 65 Years
Healthy volunteers
Accepted

Summary

Double-blind, randomized, placebo-controlled trial to assess the efficacy of Lambdalina (lidocaine cream) in reducing pain associated with laser hair removal in women.

Conditions

Interventions

TypeNameDescription
DRUGLambdalina® (Lidocaine 4% cream)Lambdaline dose: 2 g for 10 cm2.
DRUGPlaceboPlacebo dose: 2 g for 10 cm2.

Timeline

Start date
2011-05-01
Primary completion
2011-11-01
Completion
2011-11-01
First posted
2011-05-26
Last updated
2012-04-13

Locations

2 sites across 1 country: Spain

Source: ClinicalTrials.gov record NCT01360749. Inclusion in this directory is not an endorsement.

Efficacy and Safety of Lambdalina (Lidocaine Cream) Versus Placebo as an Anesthetic for Laser Hair Removal (NCT01360749) · Clinical Trials Directory